Drug – bio-affecting and body treating compositions – Immunoglobulin – antiserum – antibody – or antibody fragment,... – Structurally-modified antibody – immunoglobulin – or fragment...
Reexamination Certificate
2004-11-15
2009-06-30
Allen, Marianne P (Department: 1647)
Drug, bio-affecting and body treating compositions
Immunoglobulin, antiserum, antibody, or antibody fragment,...
Structurally-modified antibody, immunoglobulin, or fragment...
C530S351000
Reexamination Certificate
active
07553487
ABSTRACT:
The present invention is directed to methods for treating asthma.
REFERENCES:
patent: 5011778 (1991-04-01), Newman et al.
patent: 5225539 (1993-07-01), Winter et al.
patent: 5246701 (1993-09-01), Dugas et al.
patent: 5359037 (1994-10-01), Wallach et al.
patent: 5585089 (1996-12-01), Queen et al.
patent: 5596072 (1997-01-01), Culpeper et al.
patent: 5599905 (1997-02-01), Mosley et al.
patent: 5624821 (1997-04-01), Winter et al.
patent: 5648260 (1997-07-01), Winter et al.
patent: 5652123 (1997-07-01), Caput et al.
patent: 5677165 (1997-10-01), de Boer et al.
patent: 5693761 (1997-12-01), Queen et al.
patent: 5693762 (1997-12-01), Queen et al.
patent: 5696234 (1997-12-01), Zurawski et al.
patent: 5705154 (1998-01-01), Dalie et al.
patent: 5710023 (1998-01-01), Collins et al.
patent: 5717072 (1998-02-01), Mosley et al.
patent: 5747037 (1998-05-01), Noelle et al.
patent: 5783181 (1998-07-01), Browne et al.
patent: 5859205 (1999-01-01), Adair et al.
patent: 6140047 (2000-10-01), Duff et al.
patent: 6143871 (2000-11-01), Bonnefoy et al.
patent: 6180370 (2001-01-01), Queen et al.
patent: 6214559 (2001-04-01), Collins et al.
patent: 6248714 (2001-06-01), Collins et al.
patent: 6268480 (2001-07-01), Collins et al.
patent: 0506574 (1995-11-01), None
patent: 0 812 913 (1997-12-01), None
patent: 0876482 (1998-11-01), None
patent: 2 742 156 (1997-06-01), None
patent: 89/04838 (1989-06-01), None
patent: 91/09059 (1991-06-01), None
patent: 93/15766 (1993-08-01), None
patent: WO 94/04680 (1994-03-01), None
patent: 94/14975 (1994-07-01), None
patent: 95/14780 (1995-06-01), None
patent: WO 97/15663 (1997-05-01), None
patent: 97/20926 (1997-06-01), None
patent: 97/29131 (1997-08-01), None
patent: WO 97/31946 (1997-09-01), None
patent: WO 97/33913 (1997-09-01), None
patent: WO 97/47741 (1997-12-01), None
patent: WO 97/47742 (1997-12-01), None
patent: WO 98/10638 (1998-03-01), None
patent: 98/30240 (1998-08-01), None
patent: 99/29888 (1999-06-01), None
patent: 00/36103 (2000-06-01), None
patent: 00/64944 (2000-11-01), None
patent: 00/78336 (2000-12-01), None
patent: 01/23410 (2001-04-01), None
patent: 01/25282 (2001-04-01), None
patent: 01/62287 (2001-08-01), None
patent: 01/92340 (2001-12-01), None
Bost et al. In vivo treatment with anti-interleukin-13 antibodies significantly reduces the humoral immune response against an oral immunogen in mice. Immunology vol. 87 pp. 633-641 (1996).
Grunig et al. Requirement of IL-13 Independently of IL-4 in Experimental Asthma. Science vol. 282 pp. 2261-2263 (Dec. 18, 1998).
Van Der Pouw Kraan et al.Clin. Exp. Immunol., 111:129-135 (1998).
Aversa et al. (1993). “An Interleukin 4 Mutant Protein Inhibits both IL-4 or IL-13 induced Human Immunoglobulin G4 and IgE Synthesis and B Cell Proliferation: Support for a Common Component Shared by IL-4 and IL-13 Receptors”J. Exp. Med. 178: 2213-2218.
Caput et al. (1996). “Cloning and Characterization of a Specific Interleukin (IL)-13 Binding Protein Structurally Related to the IL-5 Receptor α Chain” J Biol Chem 271: 16921-16926.
Cocks et al. (1993). “IL-13 Induces Proliferation and Differentiation of Human B Cells Activated by the CD40 Ligand”Int. Immunol. 5(6): 657-663.
Collins et al. (1991). “Comparison of two distinct ligand binding chains for the IL13 receptor in the mouse” J Allergy Clin Immun 99: 287. (Abstract Only).
Donaldson et al. (1998). “The Murine IL-13 Receptor α2: Molecular Cloning, Characterization, and Comparison with Murine IL-13 Receptor α1”J Immun. 161: 2317-2324.
Grunewald et al. (1998). “An Antagonistic IL-4 Mutant Prevents Type I Allergy in the Mouse: Inhibition of the IL-4/IL-13 Receptor system Completely Abrogates Humoral Immune Response to Allergen and Development of Allergic Symptoms In Vivo”J. Immunol. 160: 4004-4009.
Hilton et al. (1996). “Cloning and characterization of a binding subunit of the interleukin 13 receptor that is also a component of the interleukin 4 receptor”Proc. Natl. Acad. Sci. USA93: 497-501.
International Search Report for PCT/US99/29493. Mailed on Apr. 25, 2000.
McKenzie et al. (1993). “Interleukin 13, a T-cell-derived cytokine that regulates human monocyte and B-cell function”Proc. Natl. Acad. Sci. USA90: 3735-3739.
Minty et al. (1993). “Interleukin-13 is a new human lymphokine regulating inflammatory and immune reponses”Nature362: 248-250.
Obiri et al. (1995). “Receptor for Interleukin 13”J. Biol. Chem. 270(15): 8797-8804.
On-line Medical Dictionary: http://cancerweb.ncl.ac.uk/omd/. Published at the Department of Medical Oncology, University of Newcastle upon Tyne. Yhe CancerWEB Project (1997-2004).
Punnonen et al. (1993). “Interleukin 13 induces interleukin 4-independent IgG4 and IgE synthesis and CD23 expression by human B cells”Proc. Natl. Acad. Sci. USA90: 3730-3734.
Punnonen et al. (1994). “IL-13 Induces Proliferation, Ig Isotype Switching, and Ig Synthesis by Immature Human Fetal B Cells”J. Immunol. 152: 1094-1102.
Shanafelt et al. (1998). “An immune cell-selective interleukin 4 agonist”Proc. Natl. Acad. Sci. USA95: 9454-9458.
Vita et al. (1995). “Characterization and Comparison of the Interleukin 13 Receptor with the Interleukin 4 Receptor on Several Cell Types”J. Biol. Chem. 270(8): 3512-3517.
Zurawski et al. (1993). “Receptors for interleukin-13 and interleukin-4 are complex and share a novel component that functions in signal transduction”EMBO J. 12: 2663-2670.
Zurawski et al. (1995). “The Primary Binding subunit of the Human Interleukin-4 Receptor Is Also a Component of the Interleukin-13 Receptor”J. Biol. Chem. 270(23): 13869-13878.
Punnonen et al., “The relative contribution of IL-4 and IL-13 to human IgE synthesis induced by activated CD4+or CD8+T cells”, J. Allergy Clin. Immunol., 100:792-801 (1997).
Bree, “IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys,” J Allergy Clin Immunol, Article in Press, pp. 1-7 (2007).
Vugmeyster et al., “Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of humanized monoclonal anti-IL-13 antibodies with different IL-13 neutralization mechanisms,” International Immunopharmacology, 8:477-483 (2008).
Fichtner-Feigl et al., “IL-13 signaling through the IL-13×2 receptor is involved in induction of TGF-B1 production and fibrosis,” Nature Medicine, 12(1): 99-106 (2006).
Kasaian et al., “Efficacy of IL-13 Neutralization in a Sheep Model of Experimental Asthma,” American Journal of Respiratory Cell and Molecular Biology, 36:368-376 (2007).
Andrews et al., “Kinetic Analysis of the Interleukin-13 Receptor Complex,” The Journal of Biological Chemistry, 277 (48):46073-46078 (2002).
Postma et al., “Genetic susceptibility to asthma-bronchial hyperresponsiveness coinherited with a major gene for atopy,” N. Engl. J. Med., 333:894-900 (1995).
Punnonen and De Vries, Oct. 1998, In: Allergy and Allergic Diseases, J.A. Denburg ed., Human Press Inc., Totowa, New Jersey, pp. 13-40.
Tekkanat et al., “IL-13-Induced Airway Hyperreactivity During Respiratory Syncytial Virus Infection Is STAT6 Dependent,” The Journal of Immunology, 166:3542-3548 (2001).
Terabe et al., “NKT cells-mediated repression of tumor immunosurveillance by IL-13 and the IL-4R-STAT6 pathway,” Nature Immunology, 1(6):515-520 (2000).
Tomkinson et al., “A Murine IL-4 Receptor Antagonist That Inhibits IL-4- and IL-13-Induced Responses Prevents Antigen-Induced Airway Eosinophilia and Airway Hyperresponsiveness,” The Journal of Immunology, 166:5792-5800, (2001).
Urban et al., “IL-13-Mediated Worm Expulsion Is B7 Independent and IFN-gama Sensitive,” The Journal of Immunology, 164:4250-4256 (2000).
Van Der Pouw Kraan et al., “The role of IL-13 in IgE synthesis by allergic asthma patients,” Clin. Exp. Immunol., 111:12
Collins Mary
Donaldson Debra
Fitz Lori
Neben Tamlyn
Whitters Matthew J.
Allen Marianne P
DeBerry Regina M
Genetics Institute LLC
Lowrie Lando & Anastasi, LLP
The Johns Hopkins University
LandOfFree
Method and compositions for treating asthma does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Method and compositions for treating asthma, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Method and compositions for treating asthma will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-4063202